Home / Health / Nemluvio: 3 Years of Sustained Atopic Dermatitis Relief
Nemluvio: 3 Years of Sustained Atopic Dermatitis Relief
30 Sep
Summary
- Nemluvio shows sustained improvements in skin lesions and itch.
- Up to 75% of patients achieved 90% eczema severity improvement.
- The drug has a consistent and well-characterized safety profile.
Galderma is presenting three-year data from the ARCADIA long-term extension study, highlighting Nemluvio's sustained benefits for moderate-to-severe atopic dermatitis. The findings, shared at the 2026 EADV Congress in Vienna, Austria, demonstrate that Nemluvio is well-tolerated and provides lasting improvements.
These results indicate significant and continuous progress in skin lesions, itch reduction, sleep quality, and overall quality of life. Notably, up to 75% of participants achieved a 90% improvement in eczema severity by Week 152.
The study also confirmed Nemluvio's consistent safety profile over three years, with no new concerns emerging. Additional data presented at EADV 2026 further support its favorable long-term safety and efficacy in related skin conditions.
Nemluvio is a monoclonal antibody targeting IL-31, a key driver of itch and inflammation. It is approved in over 40 countries for atopic dermatitis and prurigo nodularis, underscoring Galderma's commitment to advancing dermatology.
